OncoMatch/Clinical Trials/NCT07663253
Isatuximab-VRd in Transplant-Ineligible Newly Diagnosed Multiple Myeloma Patients
Is NCT07663253 recruiting? Yes, currently enrolling (Sep 2026). Studying multiple treatments including Isatuximab and Bortezomib for multiple myeloma.
Treatment: Isatuximab · Bortezomib · Lenalidomide · Dexamethasone
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Targeted therapy
Endocrine / hormonal
Other
Cancer type
Multiple Myeloma
Prior therapy
Lab requirements
Blood counts
Absolute neutrophil count (ANC) ≥1.0×10⁹/L; Platelet count ≥50×10⁹/L
Kidney function
Calculated creatinine clearance ≥30 mL/min (using Cockcroft-Gault formula)
Liver function
Total bilirubin ≤3× upper limit of normal (ULN)
Must meet corresponding laboratory test results (refer to restrictions in package inserts of combination drugs): Absolute neutrophil count (ANC) ≥1.0×10⁹/L; Platelet count ≥50×10⁹/L; Calculated creatinine clearance ≥30 mL/min (using Cockcroft-Gault formula); Total bilirubin ≤3× upper limit of normal (ULN)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07663253 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages